• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    C Reactive Protein Testing Market Trends

    ID: MRFR/LS/10636-HCR
    128 Pages
    Rahul Gotadki
    October 2025

    C reactive protein testing Market Research Report Information By Assay Type (Enzyme-linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Immunoturbidimetric Assays, and Others), By Application (Diabetes, Rheumatoid Arthritis, Cardiovascular Disease, Inflammatory Bowel Disease, and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market For...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    C Reactive Protein Testing Market Infographic
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Market Trends

    Key Emerging Trends in the C Reactive Protein Testing Market

    Several vital changes are taking place in the CRP test market due to development of diagnostic technologies, rising significance of prevention-oriented customer care and ever-growing problems with inflammatory diseases. A notable trend under consideration is the introduction of high-sensitivity CRP testing (hs-CRP) for cardiovascular risk assessment. Tests for Hs-CRP help to identify those who possess reduced CRP levels in their blood, and consequently predict cardiovascular occurrence. This movement coincides with the changing scenery of cardiovascular risk stratification, where inflammation is identified as a vital factor in cardiovascular diseases and precision assessment of their risk finds its rightful place. with the POC CRP testing becoming increasingly popular in the market, measuring CRP levels becomes easier and quicker since no lab checks are necessary. POC testing is also known timely and this makes it very suitable for the healthcare providers to make a quick decision in regards to patient care. This phenomenon indicates the need for fast and accurate diagnostic techniques, especially in leaving settings, where there is a high demand for prompt information decision-making, which can determine outcomes of patients’ lives – such as emergency rooms and primary care locations. The cardiovascular risk assessment is now only a small part of the market for testing CRP as more applications are seen in the rise of patients and test specialists. The CRP, which is one of the most widely utilized biomarkers in clinical practice, is becoming more well known as a biomarker for many inflammatory disorders such as infections and autoimmune disorders. Thus, the CRP testing is commonly used due to diverse applicability in different inflammatory disorders diagnosis and treatment monitoring by various fields of medicine. The trend of this movement highlights the specific features that are related to the role of CRP testing in helping diagnose doctors and health managers find ways for managing varied healthcare issues. The market for CRC is being normalized with the fusion of automated and high-throughput CRP monitoring systems. Round-the-clock CRP testing through automated platforms is streamlined, reduces turnaround times, and increases the efficiency of conducting activities involved in the process. This tendency meets demand for progressive scalable systems that are now needed due to the popularity of mass testing in hospitals. The application of telemedicine and remote monitoring is also making an impact on the CRP testing market, particularly during the management of chronic diseases. Since remote monitoring devices that enable self-measurement of CRP levels in one’s home are an essential tool for the tracking disease progression and inflammation, improving the accuracy required earlier from tests to avoid misdiagnosis is vital. On the one hand, this trend corresponds to the concept represented by digital healthcare reform wherein information technologies play a crucial role in enabling patient-centered care as well as increase the accessibility of diagnostic testing. Nowadays, the world of commerce is characterized by growing targets at new biomarkers and diversified testing kits.

    Market Summary

    The Global C-Reactive Protein Testing Market is projected to grow from 3.20 USD Billion in 2024 to 6.66 USD Billion by 2035, reflecting a robust growth trajectory.

    Key Market Trends & Highlights

    C-Reactive Protein Testing Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 6.89% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 6.66 USD Billion, indicating substantial growth potential.
    • in 2024, the market is valued at 3.20 USD Billion, laying a strong foundation for future expansion.
    • Growing adoption of C-Reactive Protein Testing due to increasing awareness of chronic diseases is a major market driver.

    Market Size & Forecast

    2024 Market Size 3.20 (USD Billion)
    2035 Market Size 6.66 (USD Billion)
    CAGR (2025-2035) 6.90%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    Randox Laboratories Limited, Merck KGAA (Millipore Sigma), Quest Diagnostics Incorporated, Abbott Laboratories, Zoetis Inc. (Abaxis Inc.), Thermo Fisher Scientific, Inc., Danaher Corporation (Beckman Coulter Inc.), Horiba, Ltd., Laboratory Corporation of America Holdings, F. Hoffmann-La Roche AG

    Market Trends

    Growing in chronic illnesses is driving the market growth

    Market CAGR for C reactive protein testing is being driven by the rising chronic illnesses. The rising frequency of endometriosis in women worldwide, the rise in chronic illnesses such as inflammatory disorders, rheumatoid arthritis, and cardiovascular disease, and the growing need for healthcare services. 

    For instance, 20.1 million persons aged 20 and older had coronary artery disease (CAD) in 2021, according to statistics released by the Centres for Disease Control and Prevention (CDC) and updated in October 2022. 

    Additionally, it has been stated that about 805,000 Americans get a heart attack each year. Increased CRP testing used to assess cardiovascular disease risk results from a rise in the prevalence of cardiovascular illnesses, fueling market expansion. 

    The development of portable bioanalytical tests with high specificity and sensitivity, quick reaction times, and multiplexing capabilities for on-site precise disease diagnosis and monitoring are also anticipated to benefit from improvements in nanotechnological techniques. Throughout the projection period, these developments are anticipated to increase demand for CRP testing. 

    The primary drivers of the C-reactive Protein Testing market are the rising prevalence of cardiovascular disorders worldwide and research & development to modernize the C-reactive Protein Testing techniques. According to a study done in 2019 by the American Heart Association (AHA), cardiovascular disorders cause more than 801,000 deaths in the US and about 2,200 patient fatalities.

    An aging population and a rise in diabetes mellitus incidence are also driving the market for C-reactive Protein Testing. Gastrointestinal illnesses and the associated demand for effective disease testing techniques have driven the industry. Gastrointestinal illnesses and the associated demand for effective disease testing techniques have driven the industry. 

    Adult patients with a diagnosis of a respiratory tract infection should undergo POC CRP testing in primary care, according to the National Institute of Health and Care Excellence. 

    The industry is being driven by initiatives done by government organizations to raise awareness and adoption of point of care. An increase in funding and investments for organizations doing research operations in the field and a boost for market expansion. The top cause of mortality globally, according to the World Heart Federation, is coronary heart disease. 

    According to estimates, coronary heart disease claims the lives of 3.4 million women and 3.8 million men annually. Due to their diverse optical characteristics, plasmonic nanoparticles (PNPs) are one of the technologies that may be employed for biosensing applications.. Thus, driving the C reactive protein testing market revenue.

    The increasing prevalence of chronic inflammatory diseases is driving the demand for C-Reactive Protein testing, as it serves as a crucial biomarker for assessing inflammation and guiding treatment decisions.

    Centers for Disease Control and Prevention (CDC)

    C Reactive Protein Testing Market Market Drivers

    Market Growth Projections

    The Global C-Reactive Protein Testing Market Industry is projected to experience substantial growth, with estimates indicating a market value of 3.2 USD Billion in 2024 and a remarkable increase to 6.66 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate (CAGR) of 6.89% from 2025 to 2035, reflecting the rising demand for CRP testing across various healthcare settings. The expansion of the market is likely driven by factors such as increasing prevalence of chronic diseases, advancements in diagnostic technologies, and heightened awareness of inflammatory conditions.

    Rising Prevalence of Chronic Diseases

    The increasing incidence of chronic diseases such as cardiovascular disorders and diabetes is a primary driver for the Global C-Reactive Protein Testing Market Industry. As these conditions often correlate with elevated CRP levels, healthcare providers are increasingly utilizing CRP tests for early diagnosis and monitoring. This trend is underscored by the projected market value of 3.2 USD Billion in 2024, reflecting the growing demand for effective diagnostic tools. Furthermore, the emphasis on preventive healthcare is likely to bolster the adoption of CRP testing, as it aids in assessing inflammation and guiding treatment decisions.

    Regulatory Support and Standardization

    Regulatory support and standardization initiatives are playing a crucial role in shaping the Global C-Reactive Protein Testing Market Industry. Governments and health organizations are establishing guidelines that promote the use of CRP testing in clinical settings, ensuring consistency and reliability in test results. This regulatory framework not only enhances the credibility of CRP testing but also encourages healthcare providers to adopt these tests more widely. As a result, the market is likely to benefit from increased utilization, contributing to its anticipated growth trajectory towards 6.66 USD Billion by 2035.

    Growing Awareness of Inflammatory Diseases

    There is a notable rise in public and professional awareness regarding inflammatory diseases, which significantly propels the Global C-Reactive Protein Testing Market Industry. Educational initiatives and health campaigns have highlighted the importance of CRP testing in identifying inflammation-related conditions. This awareness is expected to contribute to a market growth trajectory, with projections indicating a market size of 6.66 USD Billion by 2035. As healthcare systems increasingly recognize the role of inflammation in various diseases, the demand for CRP testing is likely to expand, leading to enhanced patient outcomes and more targeted therapies.

    Technological Advancements in Diagnostic Testing

    Innovations in diagnostic technologies are transforming the landscape of the Global C-Reactive Protein Testing Market Industry. The introduction of rapid and highly sensitive CRP testing methods enables healthcare professionals to obtain results more efficiently and accurately. These advancements not only improve patient care but also facilitate the integration of CRP testing into routine clinical practice. As a result, the market is anticipated to experience a compound annual growth rate (CAGR) of 6.89% from 2025 to 2035. Enhanced testing capabilities are likely to drive increased utilization of CRP tests, thereby expanding the market further.

    Integration of CRP Testing in Preventive Healthcare

    The integration of C-Reactive Protein testing into preventive healthcare strategies is emerging as a significant market driver within the Global C-Reactive Protein Testing Market Industry. As healthcare providers increasingly focus on preventive measures, CRP testing serves as a valuable tool for assessing inflammation and identifying at-risk individuals. This proactive approach aligns with the broader shift towards personalized medicine, where early detection can lead to timely interventions. Consequently, the market is poised for growth, with a projected value of 3.2 USD Billion in 2024, as healthcare systems prioritize preventive strategies to enhance population health.

    Market Segment Insights

    C-Reactive Protein Testing Assay Type Insights

     Based on type, the market segments of C reactive protein testing includes enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), immunoturbidimetric assays, and others. The enzyme-linked immunosorbent assay (ELISA) segment dominated the market, accounting for 35% of market revenue. 

    The rise in the market is ascribed to ELISA's many advantages, including the fact that it is an easy, fast, accurate, and reliable analytical technique for identifying and measuring human C-reactive protein in the blood. The development of this market is also significantly influenced by the rise in the incidence of chronic and infectious illnesses, the rise in the geriatric population, the surge in product releases, and collaborations with other market participants for the marketing of ELISA tests.

    C-Reactive Protein Testing Application Insights

    The C-Reactive protein testing market segmentation, based on Application, includes diabetes, rheumatoid arthritis, cardiovascular disease, inflammatory bowel disease, and others. The cardiovascular disease category generated the most income. The increase in the prevalence of CVDs is the main factor driving market development.

     A sedentary lifestyle, hypertension, obesity, and diabetes are a few risk factors for CVDs. C-reactive protein is the noninvasive biomarker for inflammation in CVDs that has been most fully studied, and there are currently several hs-CRP assays available.

    Figure 1: C reactive protein testing Market, by Application, 2022 & 2032 (USD Billion) 

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    Get more detailed insights about C Reactive Protein Testing Market Research Report 2034

    Regional Insights

    By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American C-Reactive protein testing market will dominate this market, with an increase in the adoption of cutting-edge technology and a significant focus on clinical research in North America. Given how prevalent cancer is in the United States, CRP testing is often employed.

    Further, the major countries studied in the market report are The US, Canada, German, Italy, Spain, China, Japan, France, the UK, India, Australia, South Korea, and Brazil.

    Figure 2: C REACTIVE PROTEIN TESTING MARKET SHARE BY REGION 2022 (USD Billion) 

    C REACTIVE PROTEIN TESTING MARKET SHARE BY REGION 2022

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    Europe has the second-largest market share for C-reactive protein testing. The prevalence of a well-established healthcare infrastructure, rising rates of CVD, rheumatoid arthritis, and other inflammatory diseases, and a favorable reimbursement environment. Furthermore, the German market of C reactive protein testing dominated, while the UK market of C reactive protein testing grew fastest in Europe.

    From 2023 to 2032, the Asia-Pacific C reactive protein testing Market will develop at the quickest CAGR. An increase in hospitals and a rise in hospital admissions for emergency treatment are driving the market's expansion in this area. A key factor driving market development is the rise in traffic accidents, which raises the patient population. Furthermore, China's market of C reactive protein testing had the highest market share. In contrast, the Asia-Pacific region's market of C reactive protein testing in India was the one that was growing the quickest.

    Key Players and Competitive Insights

    Leading market companies are extensively spending R&D on increasing their product lines, which will help the market of C reactive protein testing grow even more. Important market developments include new product releases, contractual agreements, acquisitions and mergers, greater investments, and collaboration with other organizations. The C reactive protein testing industry must produce cost-effective merchandise to flourish and thrive in a more competitive and increasing market climate.

    Manufacturing locally to reduce operating costs is an effective business strategy manufacturers use in the worldwide C reactive protein testing industry to serve clients and expand the market sector. The C reactive protein testing industry has provided some of the most important benefits recently. LumiraDx, Trivitron Healthcare's, and other major competitors in the market of C reactive protein testing are seeking to improve market demand by investing in R&D efforts.

    A next-generation point-of-care diagnostics business called LumiraDx is revolutionizing community-based healthcare. Since its establishment in 2014, LumiraDx has produced and sold a revolutionary diagnostic Platform that enables a wide range of tests with point-of-care performance that is on par with a lab's. 

    Governments and top healthcare organizations use LumiraDx diagnostic testing systems in clinics, urgent care centers, doctor's offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness and illness. On the LumiraDx Platform, LumiraDx offers more than 30 tests for infectious illnesses, cardiovascular diseases, diabetes, and coagulation disorders available or under development. 

    Additionally, LumiraDx offers a wide range of quick, precise, and reasonably priced COVID-19 testing options from the lab to the point of need. In January 2022, LumiraDx announced the C-reactive protein (CRP) Test CE Marking. The LumiraDx CRP Test measures C-reactive protein quantitatively and provides findings in four minutes. It is a tiny, portable, fully automated microfluidic immunoassay test. CRP testing offers crucial information to diagnose and assess infection and inflammation.

    Trivitron Healthcare's history as a medical technology firm offering cost-effective solutions has been a fascinating source of inspiration for many healthcare professionals since 1997. Hospitals, private healthcare practitioners, independent clinics and laboratories, long-term care facilities, renal care centers, and other structures offering healthcare solutions are the target markets for Trivitron's goods. Trivitron, a leader in the industry, is continually looking for new technical advancements to provide better clinical advantages at a reduced price. 

    In June 2021, In order to simplify COVID-19 diagnosis in remote, urban, and rural areas of India, Trivitron Healthcare created a mobile laboratory. The local lab offers RT-PCR assays, fast antigen tests, CLIA/Elisa IgG and IgM antibody tests, and CLIA/Elisa tests for inflammatory indicators, including D-Dimer, CRP and IL-6.

    Key Companies in the C Reactive Protein Testing Market market include

    Industry Developments

    • Q2 2024: C-reactive protein testing: Powering precision in inflammation and cardiovascular diagnostics In 2024, the C-reactive protein (CRP) testing market saw a surge in direct-to-home testing services, with new CRP testing kits designed for at-home use expanding access to diagnostics for patients managing long-term health conditions or residing in remote areas.

    Future Outlook

    C Reactive Protein Testing Market Future Outlook

    The Global C-Reactive Protein Testing Market is projected to grow at a 6.90% CAGR from 2025 to 2035, driven by rising chronic diseases, technological advancements, and increasing awareness of preventive healthcare.

    New opportunities lie in:

    • Develop point-of-care testing devices to enhance accessibility and speed of diagnosis.
    • Invest in AI-driven analytics for improved interpretation of CRP test results.
    • Expand into emerging markets with tailored marketing strategies for local healthcare needs.

    By 2035, the market is expected to achieve substantial growth, reflecting increased demand and innovation in testing solutions.

    Market Segmentation

    C reactive protein testing Regional Outlook

    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific

    C reactive protein testing Assay Type Outlook

    • Enzyme-linked immunosorbent assay (ELISA)
    • Chemiluminescence Immunoassay (CLIA)
    • Immunoturbidimetric assays
    • Others

    C reactive protein testing Application Outlook

    • Diabetes
    • Rheumatoid Arthritis
    • Cardiovascular Disease
    • Inflammatory Bowel Disease
    • Others

    Report Scope

    Report Attribute/Metric Details
    Market Size 2024    3.20 (USD Billion)
    Market Size 2025    3.42 (USD Billion)
    Market Size 2035 6.66 (USD Billion)
    Compound Annual Growth Rate (CAGR) 6.90% (2025 - 2035)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2024
    Market Forecast Period 2025 - 2035
    Historical Data 2020 - 2024
    Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
    Segments Covered Assay Type, Application, and Region
    Geographies Covered North America, Europe, Asia Pacific, and the Rest of the World
    Countries Covered The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
    Key Companies Profiled  Randox Laboratories Limited, Merck KGAA (Millipore Sigma), Quest Diagnostics Incorporated, Abbott Laboratories, Zoetis Inc. (Abaxis Inc.), Thermo Fisher Scientific, Inc., Danaher Corporation (Beckman Coulter Inc.), Horiba, Ltd., Laboratory Corporation of America Holdings, F. Hoffmann-La Roche AG
    Key Market Opportunities Medicine development
    Key Market Dynamics Increase in chronic diseases

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM

    FAQs

    What is the projected growth of the C Reactive Protein Testing market?

    The C Reactive Protein Testing market is the expected increase in total market value of 6.66 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

    What is the size of the C Reactive Protein Testing market?

    C Reactive Protein Testing market size was valued at approximately 3.2 billion USD in 2024. This figure will reach 6.66 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

    What is the CAGR of the C Reactive Protein Testing market?

    C Reactive Protein Testing market is expected to grow at a CAGR of 6.9% between 2025 and 2035.

    How much will the C Reactive Protein Testing market be worth by 2035?

    C Reactive Protein Testing market is expected to be worth of 6.66 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

    How will the C Reactive Protein Testing market perform over the next 10 years?

    Over the next 10 years the C Reactive Protein Testing market is expected to shift from usd billion 3.2 to 6.66 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

    Which region held the largest market share in the C reactive protein testing market?

    North America had the largest share in the market

    1. Executive
    2. Market Introduction
      1. Definition
        1. Limitations
    3. Research Methodology
      1. Overview
      2. Data Mining
      3. Secondary Research
      4. Primary Research
        1. Primary Interviews and Information Gathering
        2. Breakdown
      5. Forecasting
      6. Market Size Estimation
        1. Bottom-Up Approach
        2. Top-Down Approach
      7. Data Triangulation
      8. Validation
    4. Market Dynamics
      1. Overview
      2. Restraints
      3. Opportunities
    5. Market Factor
      1. Value Chain Analysis
      2. Porter’s Five Forces Analysis
        1. Bargaining Power of Suppliers
        2. Bargaining Power of Buyers
        3. Threat of New Entrants
        4. Threat of Substitutes
        5. Intensity of Rivalry
      3. COVID-19 Impact Analysis 
        1. Market Impact Analysis
        2. Regional Impact
        3. Opportunity and Threat Analysis
    6. GLOBAL C REACTIVE PROTEIN TESTING MARKET, BY Assay Type
      1. Overview
      2. Chemiluminescence Immunoassay (CLIA)
      3. Immunoturbidimetric assays
    7. GLOBAL C REACTIVE
      1. Diabetes
      2. Rheumatoid Arthritis
      3. Cardiovascular Disease
      4. Inflammatory Bowel Disease
      5. Others
    8. GLOBAL C REACTIVE PROTEIN TESTING MARKET,
      1. Overview
      2. North America
        1. US
        2. Canada
      3. Europe
        1. Germany
        2. France
        3. UK
        4. Spain
        5. Rest of Europe
      4. Asia-Pacific
        1. China
        2. Japan
        3. South Korea
        4. Australia
        5. Rest of Asia-Pacific
      5. Rest of the World
        1. Middle East
        2. Latin America
    9. Competitive Landscape
      1. Overview
      2. Competitive Analysis
      3. Market Share Analysis
      4. Competitive Benchmarking
      5. Leading Players in Terms of Number of Developments in the Global C reactive
      6. Key developments
        1. Merger & Acquisitions
        2. Joint Ventures
      7. Major Players Financial Matrix 
        1. Sales & Operating Income, 2022
        2. Major Players R&D Expenditure. 2022
    10. Company ProfileS
      1. Randox
        1. Key
        2. Company Overview
        3. Financial Overview
        4. Products Offered
        5. Key Developments
        6. SWOT Analysis
        7. Key Strategies
      2. Quest Diagnostics Incorporated
        1. Company Overview
        2. Financial Overview
        3. Products Offered
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      3. Abbott
        1. Company
        2. Financial
        3. Products
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
        7. Company Overview
        8. Financial Overview
        9. Products Offered
        10. Key Developments
        11. SWOT Analysis
        12. Key Strategies
        13. Company Overview
        14. Financial Overview
        15. Products Offered
        16. Key Developments
        17. SWOT Analysis
      4. Danaher Corporation
        1. Key
        2. Company Overview
        3. Financial Overview
        4. Products Offered
        5. Key Developments
        6. SWOT Analysis
        7. Key Strategies
        8. Company Overview
        9. Financial Overview
        10. Products Offered
        11. Key Developments
        12. SWOT Analysis
        13. Key Strategies
        14. Company Overview
        15. Financial Overview
        16. Products Offered
        17. Key Developments
        18. SWOT Analysis
        19. Key Strategies
    11. Appendix
      1. References
      2. Related Reports
    12. North America: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD
    13. Europe: C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION)
    14. FRANCE: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
    15. italy: C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION)
    16. UK: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
    17. Global C reactive protein testing Market, Share (%), BY Assay Type, 2022
    18. (%)
    19. Laboratory Corporation of America Holdings: FINANCIAL OVERVIEW SNAPSHOT

    Market Segmentation

    C Reactive Protein Testing Assay Type Outlook (USD Billion, 2018-2032)

    • Enzyme-linked immunosorbent assay (ELISA)
    • Chemiluminescence Immunoassay (CLIA)
    • Immunoturbidimetric assays
    • Others

    C Reactive Protein Testing Application Outlook (USD Billion, 2018-2032)

    • Diabetes
    • Rheumatoid Arthritis
    • Cardiovascular Disease
    • Inflammatory Bowel Disease
    • Others

    C Reactive Protein Testing Regional Outlook (USD Billion, 2018-2032)

    • North America Outlook (USD Billion, 2018-2032)

      • North America C Reactive Protein Testing by Assay Type
        • Enzyme-linked immunosorbent assay (ELISA)
        • Chemiluminescence Immunoassay (CLIA)
        • Immunoturbidimetric assays
        • Others
      • North America C Reactive Protein Testing by Application
        • Diabetes
        • Rheumatoid Arthritis
        • Cardiovascular Disease
        • Inflammatory Bowel Disease
        • Others
      • US Outlook (USD Billion, 2018-2032)

      • US C Reactive Protein Testing by Assay Type
        • Enzyme-linked immunosorbent assay (ELISA)
        • Chemiluminescence Immunoassay (CLIA)
        • Immunoturbidimetric assays
        • Others
      • US C Reactive Protein Testing by Application
        • Diabetes
        • Rheumatoid Arthritis
        • Cardiovascular Disease
        • Inflammatory Bowel Disease
        • Others
      • CANADA Outlook (USD Billion, 2018-2032)

      • CANADA C Reactive Protein Testing by Assay Type
        • Enzyme-linked immunosorbent assay (ELISA)
        • Chemiluminescence Immunoassay (CLIA)
        • Immunoturbidimetric assays
        • Others
      • CANADA C Reactive Protein Testing by Application
        • Diabetes
        • Rheumatoid Arthritis
        • Cardiovascular Disease
        • Inflammatory Bowel Disease
        • Others
    • Europe Outlook (USD Billion, 2018-2032)

      • Europe C Reactive Protein Testing by Assay Type
        • Enzyme-linked immunosorbent assay (ELISA)
        • Chemiluminescence Immunoassay (CLIA)
        • Immunoturbidimetric assays
        • Others
      • Europe C Reactive Protein Testing by Application
        • Diabetes
        • Rheumatoid Arthritis
        • Cardiovascular Disease
        • Inflammatory Bowel Disease
        • Others
      • Germany Outlook (USD Billion, 2018-2032)

      • Germany C Reactive Protein Testing by Assay Type
        • Enzyme-linked immunosorbent assay (ELISA)
        • Chemiluminescence Immunoassay (CLIA)
        • Immunoturbidimetric assays
        • Others
      • Germany C Reactive Protein Testing by Application
        • Diabetes
        • Rheumatoid Arthritis
        • Cardiovascular Disease
        • Inflammatory Bowel Disease
        • Others
      • France Outlook (USD Billion, 2018-2032)

      • France C Reactive Protein Testing by Assay Type
        • Enzyme-linked immunosorbent assay (ELISA)
        • Chemiluminescence Immunoassay (CLIA)
        • Immunoturbidimetric assays
        • Others
      • France C Reactive Protein Testing by Application
        • Diabetes
        • Rheumatoid Arthritis
        • Cardiovascular Disease
        • Inflammatory Bowel Disease
        • Others
      • UK Outlook (USD Billion, 2018-2032)

      • UK C Reactive Protein Testing by Assay Type
        • Enzyme-linked immunosorbent assay (ELISA)
        • Chemiluminescence Immunoassay (CLIA)
        • Immunoturbidimetric assays
        • Others
      • UK C Reactive Protein Testing by Application
        • Diabetes
        • Rheumatoid Arthritis
        • Cardiovascular Disease
        • Inflammatory Bowel Disease
        • Others
      • ITALY Outlook (USD Billion, 2018-2032)

      • ITALY C Reactive Protein Testing by Assay Type
        • Enzyme-linked immunosorbent assay (ELISA)
        • Chemiluminescence Immunoassay (CLIA)
        • Immunoturbidimetric assays
        • Others
      • ITALY C Reactive Protein Testing by Application
        • Diabetes
        • Rheumatoid Arthritis
        • Cardiovascular Disease
        • Inflammatory Bowel Disease
        • Others
      • SPAIN Outlook (USD Billion, 2018-2032)

      • Spain C Reactive Protein Testing by Assay Type
        • Enzyme-linked immunosorbent assay (ELISA)
        • Chemiluminescence Immunoassay (CLIA)
        • Immunoturbidimetric assays
        • Others
      • Spain C Reactive Protein Testing by Application
        • Diabetes
        • Rheumatoid Arthritis
        • Cardiovascular Disease
        • Inflammatory Bowel Disease
        • Others
      • Rest Of Europe Outlook (USD Billion, 2018-2032)

      • Rest Of Europe C Reactive Protein Testing by Assay Type
        • Enzyme-linked immunosorbent assay (ELISA)
        • Chemiluminescence Immunoassay (CLIA)
        • Immunoturbidimetric assays
        • Others
      • REST OF EUROPE C Reactive Protein Testing by Application
        • Diabetes
        • Rheumatoid Arthritis
        • Cardiovascular Disease
        • Inflammatory Bowel Disease
        • Others
    • Asia-Pacific Outlook (USD Billion, 2018-2032)

      • Asia-Pacific C Reactive Protein Testing by Assay Type
        • Enzyme-linked immunosorbent assay (ELISA)
        • Chemiluminescence Immunoassay (CLIA)
        • Immunoturbidimetric assays
        • Others
      • Asia-Pacific C Reactive Protein Testing by Application
        • Store-Based
        • Non Diabetes
        • Rheumatoid Arthritis
        • Cardiovascular Disease
        • Inflammatory Bowel Disease
        • Others
      • China Outlook (USD Billion, 2018-2032)

      • China C Reactive Protein Testing by Assay Type
        • Enzyme-linked immunosorbent assay (ELISA)
        • Chemiluminescence Immunoassay (CLIA)
        • Immunoturbidimetric assays
        • Others
      • China C Reactive Protein Testing by Application
        • Diabetes
        • Rheumatoid Arthritis
        • Cardiovascular Disease
        • Inflammatory Bowel Disease
        • Others
      • Japan Outlook (USD Billion, 2018-2032)

      • Japan C Reactive Protein Testing by Assay Type
        • Enzyme-linked immunosorbent assay (ELISA)
        • Chemiluminescence Immunoassay (CLIA)
        • Immunoturbidimetric assays
        • Others
      • Japan C Reactive Protein Testing by Application
        • Diabetes
        • Rheumatoid Arthritis
        • Cardiovascular Disease
        • Inflammatory Bowel Disease
        • Others
      • India Outlook (USD Billion, 2018-2032)

      • India C Reactive Protein Testing by Assay Type
        • Enzyme-linked immunosorbent assay (ELISA)
        • Chemiluminescence Immunoassay (CLIA)
        • Immunoturbidimetric assays
        • Others
      • India C Reactive Protein Testing by Application
        • Diabetes
        • Rheumatoid Arthritis
        • Cardiovascular Disease
        • Inflammatory Bowel Disease
        • Others
      • Australia Outlook (USD Billion, 2018-2032)

      • Australia C Reactive Protein Testing by Assay Type
        • Enzyme-linked immunosorbent assay (ELISA)
        • Chemiluminescence Immunoassay (CLIA)
        • Immunoturbidimetric assays
        • Others
      • Australia C Reactive Protein Testing by Application
        • Diabetes
        • Rheumatoid Arthritis
        • Cardiovascular Disease
        • Inflammatory Bowel Disease
        • Others
      • Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)

      • Rest of Asia-Pacific C Reactive Protein Testing by Assay Type
        • Enzyme-linked immunosorbent assay (ELISA)
        • Chemiluminescence Immunoassay (CLIA)
        • Immunoturbidimetric assays
        • Others
      • Rest of Asia-Pacific C Reactive Protein Testing by Application
        • Diabetes
        • Rheumatoid Arthritis
        • Cardiovascular Disease
        • Inflammatory Bowel Disease
        • Others
    • Rest of the World Outlook (USD Billion, 2018-2032)

      • Rest of the World C Reactive Protein Testing by Assay Type
        • Enzyme-linked immunosorbent assay (ELISA)
        • Chemiluminescence Immunoassay (CLIA)
        • Immunoturbidimetric assays
        • Others
      • Rest of the World C Reactive Protein Testing by Application
        • Diabetes
        • Rheumatoid Arthritis
        • Cardiovascular Disease
        • Inflammatory Bowel Disease
        • Others
      • Middle East Outlook (USD Billion, 2018-2032)

      • Middle East C Reactive Protein Testing by Assay Type
        • Enzyme-linked immunosorbent assay (ELISA)
        • Chemiluminescence Immunoassay (CLIA)
        • Immunoturbidimetric assays
        • Others
      • Middle East C Reactive Protein Testing by Application
        • Diabetes
        • Rheumatoid Arthritis
        • Cardiovascular Disease
        • Inflammatory Bowel Disease
        • Others
      • Africa Outlook (USD Billion, 2018-2032)

      • Africa C Reactive Protein Testing by Assay Type
        • Enzyme-linked immunosorbent assay (ELISA)
        • Chemiluminescence Immunoassay (CLIA)
        • Immunoturbidimetric assays
        • Others
      • Africa C Reactive Protein Testing by Application
        • Diabetes
        • Rheumatoid Arthritis
        • Cardiovascular Disease
        • Inflammatory Bowel Disease
        • Others
      • Latin America Outlook (USD Billion, 2018-2032)

      • Latin America C Reactive Protein Testing by Assay Type
        • Enzyme-linked immunosorbent assay (ELISA)
        • Chemiluminescence Immunoassay (CLIA)
        • Immunoturbidimetric assays
        • Others
      • Latin America C Reactive Protein Testing by Application
        • Diabetes
        • Rheumatoid Arthritis
        • Cardiovascular Disease
        • Inflammatory Bowel Disease
        • Others
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials